Metabolic signalling
Cagrilintide
What is it?
Cagrilintide is a long-acting synthetic analogue of amylin, a peptide hormone normally released alongside insulin. It belongs to a different signalling family from GLP-1 receptor agonists. Its development has focused on weight management, both alone and with semaglutide.
How it is studied
Amylin-related receptor signalling participates in satiety and the coordination of food intake. Cagrilintide was engineered for prolonged activity. This is a receptor-mediated biological effect, not evidence that a laboratory vial produces a particular amount of fat loss.
What the evidence shows
A 2021 randomised phase 2 trial compared cagrilintide with placebo and an active comparator in adults with overweight or obesity. It found a dose-related effect on body weight under controlled conditions. The compound-development paper explains the structural work leading to selection of the long-acting analogue.
Limitations & safety context
Gastrointestinal tolerability is an important part of the clinical evidence. Results for cagrilintide alone should not be substituted for results for a combination. A stated amount in milligrams does not verify sequence, salt form, formulation or clinical equivalence.
Listed specifications
| Reference | Listed contents |
|---|---|
| CGL | 5 mg |
| CGL10 | 10 mg |
Source-document quantities, not doses or a confirmation of stock. Identity, purity, component composition and suitability require separate documentation.
Research information only. No dosing, administration or treatment advice.